FRUQUINTINIB - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for fruquintinib and what is the scope of freedom to operate?
Fruquintinib
is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Fruquintinib has sixty-eight patent family members in thirty-two countries.
One supplier is listed for this compound.
Summary for FRUQUINTINIB
International Patents: | 68 |
US Patents: | 4 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 84 |
Patent Applications: | 139 |
What excipients (inactive ingredients) are in FRUQUINTINIB? | FRUQUINTINIB excipients list |
DailyMed Link: | FRUQUINTINIB at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for FRUQUINTINIB
Generic Entry Date for FRUQUINTINIB*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for FRUQUINTINIB
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Peking University | N/A |
Zhejiang Cancer Hospital | Phase 1/Phase 2 |
Fudan University | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for FRUQUINTINIB
US Patents and Regulatory Information for FRUQUINTINIB
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-001 | Nov 8, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-001 | Nov 8, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-001 | Nov 8, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-001 | Nov 8, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-002 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-002 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-002 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for FRUQUINTINIB
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2011519956 | ⤷ Sign Up | |
European Patent Office | 3191475 | FORMES CRISTALLINES DU 6-((6,7-DIMÉTHOXYQUINAZOLIN-4-YL)OXY)-N,2-DIMÉTHYLBENZOFURAN-3-CARBOXAMIDE (CRYSTALLINE FORMS OF 6-((6, 7-DIMETHOXYQUINAZOLIN-4-YL)OXY) -N,2-DIMETHYLBENZOFURAN-3-CARBOXAMIDE) | ⤷ Sign Up |
Singapore | 11201701544U | CRYSTALLINE FORMS OF 6- ( (6, 7-DIMETHOXYQUINAZOLIN-4-YL) OXY) -N,2-DIMETHYLBENZOFURAN-3-CARBOXAMIDE | ⤷ Sign Up |
China | 111018846 | 化合物晶型 (Compound crystal form) | ⤷ Sign Up |
Peru | 20170661 | FORMAS CRISTALINAS DE 6-((6,7-DIMETOXIQUINAZOLIN-4-IL)OXI)-N,2-DIMETILBENZOFURAN-3-CARBOXAMIDA | ⤷ Sign Up |
South Korea | 20170042662 | 6--N,2-디메틸벤조푸란-3-카르복사미드의 결정형 (6-67--4--N2--3- Crystalline forms of 6-67-dimethoxyquinazolin-4-yloxy-N2-dimethylbenzofuran-3-carboxamide) | ⤷ Sign Up |
Eurasian Patent Organization | 034730 | ФОРМА I СОЕДИНЕНИЯ 6-((6,7-ДИМЕТОКСИХИНАЗОЛИН-4-ИЛ)ОКСИ)-N,2-ДИМЕТИЛБЕНЗОФУРАН-3-КАРБОКСАМИДА, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И СПОСОБ ЛЕЧЕНИЯ (FORM I OF COMPOUND 6-((6,7-DIMETHOXYQUINAZOLIN-4-YL)OXY)-N,2-DIMETHYLBENZOFURAN-3-CARBOXAMIDE, METHOD OF PREPARING SAME, USE AND METHOD OF TREATMENT) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |